Announcement on Completion of First Subject Dosing in the Phase I Clinical Trial of GLR1075 Injection
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
(603087)"Gan & Lee Pharmaceuticals"Announcement on Completion of First Subject Dosing in the Phase I Clinical Trial of GLR1075 Injection
Filed with SSE · Stock code 603087 · · 2 pages · Chinese
Summary by 6ix AI
The company reported that the clinical trial has progressed smoothly, with the first dosing successfully completed recently.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Release
Gan & Lee Pharmaceuticals Co., Ltd. on 6ix
Story so far
- (603087)"Gan & Lee Pharmaceuticals"Announcement on Obtaining the Ethiopian Drug Registration Approval for Insulin Aspart Injection
- "Gan & Lee Pharmaceuticals"Announcement on Obtaining Notice of Approval for Drug Clinical Trials
- "Gan & Lee Pharmaceuticals"Announcement on Completion of Industrial and Commercial Registration Information Change
Earlier from Gan & Lee Pharmaceuticals
- (603087)"Gan & Lee Pharmaceuticals"Announcement on Obtaining the Ethiopian Drug Registration Approval for Insulin Aspart Injection
- "Gan & Lee Pharmaceuticals"Announcement on Obtaining Notice of Approval for Drug Clinical Trials
- "Gan & Lee Pharmaceuticals"Announcement on Completion of Industrial and Commercial Registration Information Change
- "Gan & Lee Pharmaceuticals"Announcement on Completion of First Subject Dosing in the Phase I Clinical Trial of GZC8072 Tablets
- "Gan & Lee Pharmaceuticals"Announcement on Obtaining Notice of Approval for Drug Clinical Trial for the New Indication of GZC8072 Tablet
Later from Gan & Lee Pharmaceuticals
All Gan & Lee Pharmaceuticals news releasesFollow Gan & Lee Pharmaceuticals into a list and get an email when it puts out news.
Follow Gan & Lee Pharmaceuticals